6 news items
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
the potential for the delivery of fresh, fit cells with a vein-to-vein time of seven days in a patient population in which rapid access to treatment
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
days in a patient population in which rapid access to treatment is vital.Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "Data
Galapagos And Blood Centers Of America Collaborate To Expand Galapagos' Decentralized CAR-T Manufacturing Network In The U.S.
GLPG
15 May 24
the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
GLPG
15 May 24
' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatments
Galapagos Q1 EPS €1.40 Vs €0.40 YoY; Revenue €62.4 Million Vs €58.6 Million YoY
GLPG
2 May 24
31 March 2023. The revenue recognition related to the exclusive access rights granted to Gilead for our drug discovery platform amounted to €57.6
so1ouoqb l4
GLPG
2 May 24
to the exclusive access rights granted to Gilead for our drug discovery platform amounted to €57.6 million for the first three months of both 2024
- Prev
- 1
- Next